TY - JOUR ID - 4159 TI - Translational Antidote Research: A Bedside to Bench Tale JO - Asia Pacific Journal of Medical Toxicology JA - APJMT LA - en SN - 2322-2611 AU - Brent, Jeffrey AD - Department of Internal Medicine (Clinical Pharmacology and Toxicology), School of Medicine, University of Colorado, Denver, CO, USA Y1 - 2015 PY - 2015 VL - 4 IS - 1 SP - 9 EP - 12 KW - antidote KW - Fomepizole KW - Methanol KW - Poisoning KW - Translational Medical Research DO - 10.22038/apjmt.2015.4159 N2 - Although antidote development should proceed in an orderly fashion from observation, to experimental and safety studies, to clinical trials, this sequence is not always precisely followed. The development of fomepizole as an antidote for toxic alcohol and glycol poisoning is an example of how this may not be the case. Interest in the development of fomepizole was spurred in the 1960s. Shortly thereafter studies characterized by administration to humans commenced. The potential value of fomepizole as an antidote for methanol poisoning was highlighted by primate experiments. Simultaneously, the utility of fomepizole was shown in an experimental model of ethylene glycol poisoning. Further studies on humans showed effectiveness of fomepizole in the treatment of disulfiram-alcohol reactions and ethylene glycol poisoning. In addition, in primate experiments, the safety of fomepizole was established as the subjects tolerated serum fomepizole concentrations over 150 times higher than therapeutic target levels. Subsequent studies have validated the efficacy of fomepizole in the treatment of ethylene glycol and methanol poisonings. Fomepizole has been found to be associated with fewer complications than the alternative alcohol dehydrogenase inhibitor, ethanol. In serious cases of methanol toxicity, fomepizole has been shown to improve survival compared to that obtained with ethanol. UR - https://apjmt.mums.ac.ir/article_4159.html L1 - https://apjmt.mums.ac.ir/article_4159_4ba53d5dabdedfd34ade93d0b1342cde.pdf ER -